<img alt="" height="1" width="1" />Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of ...Earthtimes (press release)Among one of the most common chronic conditions, irritable bowel syndrome (IBS) affects approximately 15% of adults in the United States. IBS includes ...Salix Pharma Meets FDA On Content, Format Of Pending NDA For Rifaximin<nobr>RTT News</nobr><nobr>all 11 news articles »</nobr> |